What tumors does Trametinib mainly treat?

Trametinib (Trametinib) is an antineoplastic agent that is an inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK) 1 and MEK2 in cells with B-RAF serine-threonine kinase (BRAF) V600E or V600K mutations; before starting treatment, testing is required to confirm the presence of BRAF V600E mutations; its indications include the following:

1. Melanoma: After complete resection of melanoma with BRAF V600E or V600K mutation and lymph node involvement, trametinib can be combined with Dabrafenib (Dabrafenib) as adjuvant therapy.

Trametinib is indicated alone or in combination with dabrafil for the treatment of unresectable or metastatic melanoma in selected patients with BRAF V600E or V600K mutations. Before initiating monotherapy or combination therapy, an FDA-approved in vitro diagnostic test (such as the BRAF kit) is required to confirm the presence of the BRAF V600E or V600K mutation.

Use as a single agent is not recommended in patients with melanoma whose disease has progressed after receiving a BRAF inhibitor.

2. Non-small cell lung cancer (NSCLC): Trametinib is used in combination with dabrafenib for the treatment of metastatic NSCLC in patients with BRAF V600E mutations. When used in combination, it is designated as an orphan drug by the FDA. Before starting treatment, an FDA-approved diagnostic test (such as the BRAF kit) is required to confirm the presence of the BRAF V600E mutation.

3. Anaplastic thyroid cancer (ATC): In combination with dabrafenib for the treatment of locally advanced or metastatic anaplastic ATC in patients with BRAF V600E mutations, when combined for this purpose, it is designated as an orphan drug by the FDA.

Testing is required to confirm the presence of the BRAF V600E mutation before starting treatment; there are currently no FDA-approved diagnostic tests for detecting BRAF V600E in anaplastic thyroid cancer.

4. BRAF V600E-mutated solid tumors: Trametinib is indicated in combination with dabrafenib for the treatment of adult and pediatric patients ≥6 years of age who have unresectable or metastatic solid tumors (excluding colorectal cancer) that are associated with BRAF V600E mutations and have progressed after prior treatment and for whom there is no satisfactory alternative treatment.

Doctors may adjust the trametinib dose based on the patient's response to treatment and any side effects experienced. Patients may swallow the tablets whole without breaking or crushing them; if a patient vomits after taking trametinib, do not take another dose. Continue regular dosing schedule.